Propafenone interaction with CYP3A4 inhibitors in man

被引：0
|
作者：
Munoz, CE
Ito, S
Bend, JR
Tesoro, A
Freeman, D
Spence, JD
Bailey, DG
机构：
[1] UNIV WESTERN ONTARIO,DEPT PHARMACOL & TOXICOL,LONDON,ON,CANADA
[2] UNIV TORONTO,HOSP SICK CHILDREN,TORONTO,ON M5S 1A1,CANADA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1997年 / 61卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：PI69 / PI69
页数：1
相关论文
共 50 条
  • [31] MD Investigation on the Interaction between Carbamazepine and Two CYP Isoforms, CYP3A4 and CYP3A5
    Liu, Shuhui
    Xu, Yang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [32] Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone
    Lee, Lucy
    Thoolen, Martin
    Ma, Jiyuan
    Kaushik, Diksha
    Golden, Lee
    Kong, Ronald
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (12): : 1283 - 1290
  • [33] CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity
    García-Martín, E
    Martínez, C
    Pizarro, RM
    García-Gamito, FJ
    Gullsten, H
    Raunio, H
    Agúndez, JAG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) : 196 - 204
  • [34] Mechanism-based inhibition of CYP3A4 and CYP3A5 by seven inhibitors.
    Patki, KC
    von Moltke, LL
    Greenblatt, DJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P83 - P83
  • [35] THE PROTEIN KINASE INHIBITORS MIDOSTAURIN AND NINTEDANIB ARE TIME-DEPENDENT INHIBITORS OF CYP3A4
    Filppula, A.
    Mustonen, T.
    Backman, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 12 - 12
  • [36] Synthesis of 8-geranyloxypsoralen analogues and their evaluation as inhibitors of CYP3A4
    Row, E. C.
    Brown, S. A.
    Stachulski, A. V.
    Lennard, M. S.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (11) : 3865 - 3871
  • [37] Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa)
    Tsukamoto, S
    Aburatani, M
    Ohta, T
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2005, 2 (02) : 223 - 226
  • [38] GLOBAL ANALYSIS OF CYP3A4 AND CYP3A5 GENOTYPE ON IN VIVO CLEARANCE OF CYP3A4 SUBSTRATES.
    Quinney, S. K.
    Schwartz, J. B.
    Hall, S. D.
    Gorski, J. C.
    Li, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S49 - S49
  • [39] Concomitant use of ivabradine and cyp3a4 inhibitors in critical cardiac patients
    Ariff, Mohamed A.
    Abd Hadi, H.
    Nay, T. W.
    Thoulath, M., I
    Aktifanus, Jauhari A. T.
    Mutaya, S. M.
    Ismail, S. N.
    Jafar, N.
    Nalliah, S.
    Khairuddin, A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 105 - 105
  • [40] CYP3A4 inhibitors most frequent cause of potential statin interactions
    Reactions Weekly, 2005, 1044-1045 (1) : 5 - 5
12345